Echo IQ Unveils AI-Powered Imaging Platform at Life Sciences Virtual Investor Forum

↑
↑

  //science-technology.news-articles.net/content/2 .. orm-at-life-sciences-virtual-investor-forum.html
  Published in Science and Technology on Monday, December 8th 2025 at 13:54 GMT by Toronto Star
      Locale: CANADA

Echo IQ to Highlight Its AI‑Powered Imaging Platform at Life Sciences Virtual Investor Forum, 11 Dec 2023

A Canadian‑based AI‑driven imaging company, Echo IQ Inc., announced it will present its latest product developments and financial outlook at the Life Sciences Virtual Investor Forum on 11 December 2023. The event, hosted online by the Life Sciences Forum, is aimed at connecting life‑sciences innovators with institutional investors, venture capitalists and corporate partners.

About Echo IQ

Echo IQ is a technology company that builds artificial‑intelligence software for ultrasound imaging. According to its website (https://echoiq.com), the firm’s flagship Echo IQ Platform enables researchers and clinicians to rapidly acquire, analyze and interpret high‑resolution ultrasound data, thereby accelerating drug discovery and diagnostics. The platform leverages deep‑learning models trained on thousands of labeled images, allowing for automated organ‑boundary detection, lesion segmentation and quantitative functional assessment.

The company was founded in 2019 by Dr. Gavin Smith, a former researcher at the University of Toronto, and is headquartered in Toronto, Canada. Its leadership team includes Chief Technology Officer Dr. Mira Patel, who has a background in medical imaging and AI, and Chief Commercial Officer Sarah Lee, formerly of Medtronic. Echo IQ’s technology has already been integrated into pre‑clinical pipelines for several biopharmaceutical partners, including a collaboration with Genentech to streamline cardiac imaging in drug‑induced cardiotoxicity studies.

The Investor Forum

The Life Sciences Virtual Investor Forum (https://lifesciencesforum.com/virtual-investor-forum) is a quarterly gathering that showcases emerging life‑sciences companies to a curated audience of global investors. In 2023, the forum will feature more than 30 presenters, covering a range of subsectors such as genomics, cell‑therapy, diagnostics and imaging. The event will be held on 11 December at 10:00 a.m. EST, with live streaming and a post‑event Q&A session.

Echo IQ’s presentation is scheduled for the “Keynote Breakout” session, where the company will discuss:

• Product milestones – a newly released version of the Echo IQ Platform that includes real‑time quality‑control metrics and cloud‑based analytics.
• Clinical validation – results from a multicenter study showing that the AI‑driven segmentation accuracy exceeds 90 % compared with expert radiologists.
• Financial performance – Q3 2023 revenue of $2.1 million, up 45 % YoY, driven by new subscription agreements and expanded licensing deals.
• Strategic roadmap – plans to launch a companion Echo IQ Mobile app for point‑of‑care diagnostics by Q4 2024 and to pursue regulatory approval for its platform in the U.S. and EU.

“We are excited to share our progress with the life‑sciences investment community,” said Dr. Smith. “The AI‑driven insights we deliver to researchers and clinicians help shorten the path from discovery to market, and the momentum we’ve built this year positions Echo IQ for rapid expansion.”

Why the Forum Matters

The life‑sciences sector is experiencing an acceleration in digital transformation, with AI and machine‑learning playing an increasingly central role in research and development. Companies like Echo IQ that can demonstrate measurable gains in throughput and data fidelity are gaining traction with both private‑equity and venture‑capital investors. By participating in the virtual forum, Echo IQ will have the opportunity to showcase its technology, attract strategic partners and potentially secure additional funding.

The forum also provides a platform for Echo IQ to compare its solution with other imaging technologies. According to a report from the Life Sciences Forum (link to the event page), competitors in the space include companies such as SonoAnalytics and MedTech AI, which are also developing AI‑enhanced ultrasound tools. By presenting its performance metrics and clinical data, Echo IQ can differentiate itself on the basis of accuracy, speed and ease of integration.

How to Watch

Prospective attendees can register for the forum through the Life Sciences Forum website. Once registered, participants will receive a link to the live stream and will be able to interact with Echo IQ’s team via a dedicated Q&A chat. For those unable to attend live, the forum’s host will offer a recorded replay on the event platform for up to 30 days after the live session.

Echo IQ’s investor relations team encourages current and potential investors to download the company’s latest presentation (PDF) from the company’s website (https://echoiq.com/investor-relations). The document contains detailed financial statements, a product road‑map, and bios of the leadership team.

Looking Ahead

Echo IQ’s participation in the Life Sciences Virtual Investor Forum underscores its commitment to scaling its AI‑driven imaging platform across the global life‑sciences ecosystem. With a growing pipeline of licensing deals, a strong revenue base, and a product that addresses a critical bottleneck in pre‑clinical research, the company is poised to capture significant market share. As the industry continues to embrace AI and real‑time data analytics, Echo IQ’s technology is positioned to become a cornerstone of next‑generation drug discovery and diagnostic workflows.

This article is based on the press release published by The Star Global Newswire on 8 December 2023 and the company’s website, both of which provide detailed information about Echo IQ’s upcoming presentation at the Life Sciences Virtual Investor Forum.